Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS

NCT03077607 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03077607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2016
Completion date
January 20, 2018
Enrollment
36 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors